Literature DB >> 21440209

Biomarkers: the future.

Steven P LaRosa1, Steven M Opal.   

Abstract

The future application of biomarkers in critical illness will be to select and guide therapy. Specific biomarkers could identify a pathophysiologic perturbation or noxious mediator to counteract or the need to replete a deficient protective protein. Functional genomics could identify patients at risk for illness or at risk for a poor outcome in critical illness. Genetic expression studies could help differentiate patients with sepsis from those with noninfectious inflammation and could also help to monitor illnesses over time. Expressional and functional proteomics could lead to the identification of new biomarkers and organ-specific therapies.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21440209     DOI: 10.1016/j.ccc.2010.12.012

Source DB:  PubMed          Journal:  Crit Care Clin        ISSN: 0749-0704            Impact factor:   3.598


  6 in total

1.  An integrated clinico-metabolomic model improves prediction of death in sepsis.

Authors:  Raymond J Langley; Ephraim L Tsalik; Jennifer C van Velkinburgh; Seth W Glickman; Brandon J Rice; Chunping Wang; Bo Chen; Lawrence Carin; Arturo Suarez; Robert P Mohney; Debra H Freeman; Mu Wang; Jinsam You; Jacob Wulff; J Will Thompson; M Arthur Moseley; Stephanie Reisinger; Brian T Edmonds; Brian Grinnell; David R Nelson; Darrell L Dinwiddie; Neil A Miller; Carol J Saunders; Sarah S Soden; Angela J Rogers; Lee Gazourian; Laura E Fredenburgh; Anthony F Massaro; Rebecca M Baron; Augustine M K Choi; G Ralph Corey; Geoffrey S Ginsburg; Charles B Cairns; Ronny M Otero; Vance G Fowler; Emanuel P Rivers; Christopher W Woods; Stephen F Kingsmore
Journal:  Sci Transl Med       Date:  2013-07-24       Impact factor: 17.956

Review 2.  New role of biomarkers: mid-regional pro-adrenomedullin, the biomarker of organ failure.

Authors:  Francisco Valenzuela-Sánchez; Blanca Valenzuela-Méndez; Juan Francisco Rodríguez-Gutiérrez; Ángel Estella-García; María Ángela González-García
Journal:  Ann Transl Med       Date:  2016-09

3.  Fc Gamma Receptor IIA (CD32A) R131 Polymorphism as a Marker of Genetic Susceptibility to Sepsis.

Authors:  Jaqueline Beppler; Patrícia Koehler-Santos; Gabriela Pasqualim; Ursula Matte; Clarice Sampaio Alho; Fernando Suparregui Dias; Thayne Woycinck Kowalski; Irineu Tadeu Velasco; Renato C Monteiro; Fabiano Pinheiro da Silva
Journal:  Inflammation       Date:  2016-04       Impact factor: 4.092

Review 4.  Clinical application of sepsis biomarkers.

Authors:  Vinoth Sankar; Nigel R Webster
Journal:  J Anesth       Date:  2012-10-30       Impact factor: 2.078

Review 5.  Bench-to-bedside review: future novel diagnostics for sepsis - a systems biology approach.

Authors:  Simon Skibsted; Manoj K Bhasin; William C Aird; Nathan I Shapiro
Journal:  Crit Care       Date:  2013-10-04       Impact factor: 9.097

6.  Bioinformatical Analysis of Organ-Related (Heart, Brain, Liver, and Kidney) and Serum Proteomic Data to Identify Protein Regulation Patterns and Potential Sepsis Biomarkers.

Authors:  Andreas Hohn; Ivan Iovino; Fabrizio Cirillo; Hendrik Drinhaus; Kathrin Kleinbrahm; Lennert Boehm; Edoardo De Robertis; Jochen Hinkelbein
Journal:  Biomed Res Int       Date:  2018-03-21       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.